article Open AccessTop 1% cited
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
BMC Cancer · 2014 · Vol. 14(1) · pp. 177–177
Torsten O. Nielsen✉(BC Cancer Agency)Brett Wallden(Nanostring Technologies (United States))Carl SchaperSean Ferree(Nanostring Technologies (United States))Shuzhen Liu(BC Cancer Agency)Dongxia Gao(BC Cancer Agency)Garrett Barry(BC Cancer Agency)Naeem Dowidar(Nanostring Technologies (United States))Malini Maysuria(Nanostring Technologies (United States))James J. Storhoff(Nanostring Technologies (United States))
Abstract
The analytical performance of NanoString's Prosigna assay has been validated using FFPE breast tumor specimens across multiple clinical testing laboratories.
Molecular Biology Techniques and ApplicationsGene expression and cancer classificationBreast Cancer Treatment StudiesBreast cancerReproducibilityMedicineOncologyInternal medicineSurgical oncologyCancerPathologyChemistry
MeSH terms
Breast NeoplasmsFemaleFormaldehydeHumansPrognosisRNABiomarkers, TumorReproducibility of ResultsGene Expression Regulation, NeoplasticParaffin EmbeddingValidation Studies as TopicPathology, Molecular
Funding
- BC Cancer Agency
Citations
304
FWCI
17.65
field-weighted impact
References
46
Percentile
100%
vs. same field & year
Citations per year
Cited by
Coming of age: ten years of next-generation sequencing technologies
Nature Reviews Genetics · 2016 · 4,335 citations
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Annals of Oncology · 2015 · 1,820 citations
References
Molecular portraits of human breast tumours
Nature · 2000 · 16,173 citations
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
New England Journal of Medicine · 2004 · 6,318 citations
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
Journal of Clinical Oncology · 2007 · 2,211 citations
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Journal of Clinical Oncology · 2006 · 4,462 citations
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Journal of Clinical Oncology · 2009 · 4,815 citations
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
New England Journal of Medicine · 2002 · 6,503 citations
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
Clinical Cancer Research · 2010 · 818 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.